Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes

PR Newswire/Les Echos/ 
PRESS RELEASE 
 Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for 
               Optimal Care for Young People with Diabetes 
Paris, France, and Boston, Mass., - November 14, 2012 - Sanofi (EURONEXT: SAN
and NYSE: SNY) and T1D Exchange, a non-profit organization focused on type 1
diabetes, announced today on World Diabetes Day that they will collaborate on
the TEENs registry study. The aim of the study is to provide the type 1 diabetes
community with a better understanding of how children, adolescents and young
adults are currently living with type 1 diabetes, and to deliver recommendations
for better disease management and patients outcomes. 
TEENs, also known as the "Glycemic control and quality of life in children,
adolescents, and young adults with type 1 diabetes mellitus described in a
worldwide, cross-sectional study in 2012," is a multinational, observational,
cross-sectional study that will evaluate the percentage of type 1 diabetes
patients between the ages of 8 and 25 with controlled glycemia, as measured by
hemoglobin A1c (HbA1c). Secondary outcomes will include measurements of quality
of life and emotional status, the relationship between glycemic control and
quality of life, and the impact of factors such as medical care on these two
measurements. 
"To better understand how to treat young people with type 1 diabetes, we need to
know how exactly they are living with the disease. Our goal with the TEENs study
is to examine how clinical factors such as glycemic control impact the quality
of life of this particularly vulnerable group of young people with diabetes,"
said Riccardo Perfetti, MD, Vice President Medical Affairs, Global Diabetes,
Sanofi. "TEENs is another example of Sanofi's ongoing commitment to further
develop the understanding of optimal type 1 diabetes care." 
The TEENs study will enroll more than 7,000 people with type 1 diabetes in 20
countries, with a sample representative of the typical medical care in the
respective country. In the US, Sanofi works in partnership with T1D Exchange for
the recruitment of the young study participants and for implementation of this
study. Worldwide, Sanofi partners with various clinic centers, hospitals, and
healthcare professionals. 
"We are excited to support Sanofi and the TEENs study with T1D Exchange's
patient registry and extensive clinic network in the US. We are also honored to
be designated by Sanofi as a clinical trial Center of Excellence," said Dana
Ball, CEO and Cofounder of the T1D Exchange. "This collaboration demonstrates
the unique efficiencies and capabilities that partnerships with
foundation-driven clinical exchanges can create." 
Data will be collected from healthcare professionals, parents or guardians, and
patients. Anticipated outcomes include: identification of predictive factors for
glucose control and acute complications of type 1 diabetes, better understanding
of unmet needs of young people with type 1 diabetes in different age groups,
documentation of insulin regimens in young people with type 1 diabetes, and
description of the patient journey from pediatric to adult care services. 
Results from the TEENs study will be presented at scientific congresses in 2013
and in 2014. 
About Diabetes
Diabetes is a chronic disease that occurs as type 1 diabetes, which is an
autoimmune disease characterized by the lack of insulin (the hormone that
regulates blood glucose concentrations) production by the pancreas, and type 2,
a metabolic disorder in which there are two main biological defects: a deficient
production of insulin and reduced ability of the body to respond to the insulin
being produced. Type 1 and type 2 diabetes are characterized by an increase in
blood glucose concentrations (hyperglycemia). Over time, uncontrolled
hyperglycemia leads to the macrovascular and microvascular complications of
diabetes. Macrovascular complications, which affect the large blood vessels,
include heart attack, stroke and peripheral vascular disease. Microvascular
complications affect the small blood vessels of the eyes (retinopathy), kidney
(nephropathy) and nerves (neuropathy). More than 18 million people worldwide are
living with type 1 diabetes. And, the incidence of type 2 diabetes is growing at
an alarming rate, with nearly 348 million people worldwide living with the
condition today. 
About T1D Exchange
T1D Exchange is a non-profit organization with the mission to improve outcomes
of people touched by type 1 diabetes by accelerating the discovery of new
approaches to research and development. It connects the disparate stakeholders
in the type 1 diabetes community by combining the critical components of
traditional clinical research with the expanding fields of health information
technology and social networking. 
T1D Exchange evolved as a solution to mitigate barriers and inefficiencies for
type 1 diabetes research and development. It is a personalized exploration
platform anchored in health informatics: T1D Exchange consists of Glu, an
interactive website with mobile capabilities for patients and caregivers; a
network of 69 clinics across the United States; and a biorepository comprising
clinically annotated patient biological samples. T1D Exchange was fou nded in
2011 through a grant from The Leona M. and Harry B. Helmsley Charitable Trust.
More information is available at www.t1dexchange.org. 
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by valuable
insights that come from listening to and engaging with people living with
diabetes, the Company is forming partnerships to offer diagnostics, therapies,
services and devices, including innovative blood glucose monitoring systems.
Sanofi markets both injectable and oral medications for people with type 1 or
type 2 diabetes. Investigational compounds in the pipeline include an injectable
GLP-1 receptor agonist being studied as a single agent, in combination with
basal insulin, and/or in combination with oral antidiabetic agents. 
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY). 
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment policies and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those listed
under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Statements" in Sanofi's annual report on Form 20-F for the year ended December
31, 2011. Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information or
statements. 
Contacts: 
Sanofi                                T1D Exchange 
Corporate Media Relations             Ellen Giller
Marisol Peron                         Tel: + 1 (617) 892-6132
Tel: +33 1 53 77 45 02                E-mail: egiller@t1dexchange.org
Mobile: +33 6 08 18 94 78
E-mail: mr@sanofi.com 
Global Diabetes Division Communications 
Tilmann Kiessling
Mobile: +49 172 61 59 291
E-mail: TilmannKiessling@sanofi.com 
US Diabetes Communications Susan Brooks
Tel: +1 (0) 9 08 98 16 56 6 
Mobile: +1 (0) 2 01 57 24 99 4 
Susan.Brooks@sanofi.com 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Nov/14/2012 12:03 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.